Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALNY 
Alnylam Pharmaceuticals Inc (ALNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ALNY (3-star) is a STRONG-BUY. BUY since 69 days. Profits (60.09%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
33 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $424.64
1 Year Target Price $424.64
| 12 | Strong Buy |
| 12 | Buy |
| 7 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.43% | Avg. Invested days 27 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 58.03B USD | Price to earnings Ratio - | 1Y Target Price 424.64 |
Price to earnings Ratio - | 1Y Target Price 424.64 | ||
Volume (30-day avg) 33 | Beta 0.25 | 52 Weeks Range 205.87 - 449.52 | Updated Date 08/15/2025 |
52 Weeks Range 205.87 - 449.52 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate -0.6561 | Actual 0.32 |
Profitability
Profit Margin -12.96% | Operating Margin (TTM) -2.09% |
Management Effectiveness
Return on Assets (TTM) -2.63% | Return on Equity (TTM) -257.83% |
Valuation
Trailing PE - | Forward PE 161.29 | Enterprise Value 56472091310 | Price to Sales(TTM) 23.57 |
Enterprise Value 56472091310 | Price to Sales(TTM) 23.57 | ||
Enterprise Value to Revenue 22.94 | Enterprise Value to EBITDA 204.85 | Shares Outstanding 131079000 | Shares Floating 126154376 |
Shares Outstanding 131079000 | Shares Floating 126154376 | ||
Percent Insiders 3.79 | Percent Institutions 98.15 |
Upturn AI SWOT
Alnylam Pharmaceuticals Inc
Company Overview
History and Background
Alnylam Pharmaceuticals was founded in 2002 in Cambridge, MA, pioneering RNA interference (RNAi) therapeutics. Significant milestones include FDA approval of Onpattro in 2018, the first RNAi therapeutic. The company has evolved from a research-focused entity to a commercial biopharmaceutical company.
Core Business Areas
- RNAi Therapeutics: Develops and commercializes RNAi therapeutics for genetically defined diseases.
- Genetic Medicines: Focuses on developing medicines targeting the genetic basis of disease.
Leadership and Structure
Alnylam is led by CEO Yvonne Greenstreet. The organizational structure includes departments focused on research, development, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Onpattro (patisiran): An RNAi therapeutic for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy. Global sales in 2023 were $677 million. Competitors include Pfizer's Vyndaqel/Vyndamax and Ionis Pharmaceuticals' Tegsedi.
- Amvuttra (vutrisiran): An RNAi therapeutic for hATTR amyloidosis with polyneuropathy, administered subcutaneously. Global sales in 2023 were $428 million. Competitors include Onpattro and Pfizer's Vyndaqel/Vyndamax.
- Oxlumo (lumasiran): An RNAi therapeutic for primary hyperoxaluria type 1 (PH1). Global sales in 2023 were $174 million. Currently, it doesn't have any direct competitors.
- Givlaari (givosiran): An RNAi therapeutic for acute hepatic porphyria (AHP). Global sales in 2023 were $177 million. Competitors include Dojindo's Coprexa and Recordati Rare Diseases' Panhematin.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation and regulatory approvals. Alnylam operates within the rare disease market, which benefits from orphan drug designations and high unmet needs.
Positioning
Alnylam is a leader in RNAi therapeutics, with a strong patent portfolio and first-mover advantage. The company faces competition from larger pharmaceutical companies and other RNAi developers.
Total Addressable Market (TAM)
The total addressable market for RNAi therapeutics and genetic medicines is estimated to be in the billions of dollars. Alnylam is positioned to capture a significant portion of this market through its pipeline of novel therapies.
Upturn SWOT Analysis
Strengths
- Pioneer in RNAi therapeutics
- Strong patent portfolio
- FDA-approved products
- Robust pipeline
- Experienced management team
Weaknesses
- High research and development costs
- Reliance on a limited number of products
- Competition from larger pharmaceutical companies
- Regulatory hurdles
Opportunities
- Expansion into new therapeutic areas
- Partnerships and collaborations
- Geographic expansion
- New RNAi delivery technologies
- Treatment for larger diseases
Threats
- Patent expiration
- Clinical trial failures
- Competition from biosimilars
- Pricing pressures
- Changes in regulatory environment
Competitors and Market Share
Key Competitors
- PFE
- IONS
Competitive Landscape
Alnylam has a first-mover advantage in RNAi therapeutics, but faces competition from established pharmaceutical companies with broader pipelines and commercial infrastructure.
Major Acquisitions
Sirna Therapeutics
- Year: 2006
- Acquisition Price (USD millions): 25
- Strategic Rationale: Acquired Sirna Therapeutics to enhance its RNAi technology platform and expand its intellectual property portfolio.
Growth Trajectory and Initiatives
Historical Growth: Alnylam has experienced significant revenue growth following the approval of its first RNAi therapeutics.
Future Projections: Analysts project continued revenue growth driven by new product launches and market penetration.
Recent Initiatives: Alnylam is focused on expanding its pipeline, advancing clinical trials, and commercializing new products.
Summary
Alnylam is a leader in RNAi therapeutics, with approved products and a robust pipeline. The company is showing strong growth in the rare disease market. Alnylam is facing competition and high R&D costs, so it must continue its innovative development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Alnylam Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on publicly available data. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alnylam Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2004-05-28 | CEO & Director Dr. Yvonne L. Greenstreet M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2230 | Website https://www.alnylam.com |
Full time employees 2230 | Website https://www.alnylam.com | ||
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.